Skin and Mucosal Delivery (Focus Group - SMD)
With several well-known large-volume subcutaneous (SC) oncology drugs, such as daratumumab, trastuzumab, rituximab, nivolumab, and pembrolizumab, either approved or in trials, understanding how administration volume impacts drug development is critical. Subcutaneous adoption is often limited by the perception that delivery volumes must stay below 3 milliliters without a permeation enhancer. This misconception hampers SC oncology drug prioritization and stifles innovation. Our survey was conducted to investigate decision-making processes surrounding large-volume SC oncology drug candidates.